• Policy
• Pfizer applies for reimb of its COVID-19 Tx Paxlovid
• by Lee, Tak-Sun Oct 6, 2023 05:36am

• Policy
• Reducing criminal liability for essential healthcare
• by Lee, Jeong-Hwan Oct 6, 2023 05:36am

• Policy
• Health plans expected to be implemented after NA audit
• by Lee, Jeong-Hwan Oct 5, 2023 05:27am

• Policy
• Medical expenses exceed ₩1 trillion
• by Lee, Tak-Sun Oct 4, 2023 05:35am

• Policy
• New pharmaceutical data protection system begins
• by Lee, Jeong-Hwan Oct 4, 2023 05:35am

• Policy
• Legislation to prevent reverse-payment agreements
• by Lee, Jeong-Hwan Oct 4, 2023 05:35am

• Policy
• Myung-in & Hwan-in are launching Fycompa’s generics
• by Lee, Tak-Sun Sep 27, 2023 05:44am

• Policy
• MFDS grants EUA of Moderna’s adapted COVID-19 vaccine
• by Lee, Hye-Kyung Sep 27, 2023 05:44am

• Policy
• Resolving Conflicts in Non-face-to-face Medical treatment
• by Lee, Jeong-Hwan Sep 27, 2023 05:44am

• Policy
• Why did the original Ninlaro voluntarily cut its price 34%
• by Lee, Tak-Sun Sep 27, 2023 05:44am